Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026

Forte Biosciences, Inc.

2025-Q3 EPS reported -$3.26

Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.
R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.
Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.
FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.
Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.